Developing robust bioanalytical methods for novel modalities like CAR-NK cells and mRNA-LNP constructs requires a purpose-built strategy. Off-the-shelf assays are insufficient for characterizing the complex pharmacokinetics (PK) and pharmacodynamics (PD) of these therapies. The following framework outlines a strategy for creating and validating bespoke assays, focusing on key endpoints such as cell persistence, payload quantification, and protein expression kinetics to support IND-enabling studies. The approach prioritizes scientific rigor and regulatory alignment to de-risk clinical translation.

How do you approach ligand-binding assay (LBA) development for a novel CAR-NK construct with no existing reagents?

We initiate a parallel workflow. Our team begins by generating custom monoclonal antibodies or sourcing recombinant proteins against the novel CAR domain. Concurrently, we establish the assay framework using surrogate positive controls to define parameters like buffer conditions, incubation times, and detection systems. This dual approach significantly compresses the timeline from initial development to a qualified, fit-for-purpose assay.

What is your strategy for quantifying mRNA payload versus the LNP carrier in tissue samples?

We employ a multi-assay strategy. A validated RT-qPCR method is used to specifically quantify the mRNA payload, providing data on tissue concentration and stability. For the LNP carrier, we develop methods to quantify a specific lipid component, often using liquid chromatography with tandem mass spectrometry (LC-MS/MS). Correlating these two datasets provides a comprehensive view of delivery vehicle integrity and payload delivery efficiency.

How do you ensure assay reproducibility for cell therapies with inherent donor-to-donor variability?

We address this by establishing a robust quality control (QC) system. This involves creating a well-characterized bank of reference cells from multiple donors and defining stringent acceptance criteria for assay performance based on these standards. During validation, we assess the method’s tolerance for variability by testing it against this diverse cell panel, ensuring the assay is rugged enough for clinical sample analysis.

Which platforms do you recommend for measuring biomarkers related to cytokine release syndrome (CRS)?

For CRS monitoring, we recommend high-plex immunoassays on platforms like MSD or Luminex. These platforms allow for the simultaneous quantification of a broad panel of relevant cytokines (e.g., IL-6, IFN-γ, TNF-α) from a minimal sample volume. This provides a comprehensive pharmacodynamic snapshot for evaluating the safety profile of immuno-oncology and cell therapies.

Key Bioanalytical Endpoints by Modality

A platform-agnostic approach is required to select the right tool for each scientific question. The table below outlines the primary considerations and common technology platforms for CAR-NK and mRNA-LNP programs.

This tailored analytical strategy is a core component of our programs. Since the Franklin Biolabs brand launch in 2024, programs managed by our core scientific leadership have maintained a 100% IND success rate since 2019. This record is built on a deep understanding of the unique challenges posed by each therapeutic modality.